RESUMEN
Abundant preclinical work showed that in Crohn's disease (CD), the defective activity of the immunosuppressive cytokine tumor necrosis factor (TGF)-ß1 due to high levels of the intracellular inhibitor Smad7 contributes to amplify the tissue-damaging inflammatory response. Consistently, phase I and II studies documented clinical and endoscopic benefit in active CD patients treated with mongersen, an oral antisense oligonucleotide targeting Smad7. However, a multicenter, randomized, double-blind, placebo-controlled, phase III study was prematurely discontinued as a futility analysis showed that mongersen was not effective in CD patients. The reasons why the phase III study failed despite the fact that previous clinical trials documented the efficacy of the drug remain unknown. The primary objective of this Viewpoint was to provide clues about the factors explaining discrepancies among the clinical trials. We illustrate the recent data indicating that the various batches of mongersen, used during the phase III program, are chemically different, with some of them being unable to downregulate Smad7 expression. Overall, these findings suggest the necessity of new clinical studies to further evaluate the efficacy of chemically homogenous batches of mongersen in patients with inflammatory bowel diseases (IBDs), and, at the same time, they can help understand the failure of other clinical trials with antisense oligonucleotides in IBD (i.e. alicaforsen).
Asunto(s)
Enfermedad de Crohn , Enfermedades Inflamatorias del Intestino , Terapia Biológica , Enfermedad de Crohn/tratamiento farmacológico , Enfermedad de Crohn/genética , Humanos , Inmunosupresores/uso terapéutico , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Oligonucleótidos Antisentido/farmacología , Oligonucleótidos Antisentido/uso terapéutico , Proteína smad7/genética , Proteína smad7/metabolismo , Proteína smad7/uso terapéuticoRESUMEN
Osteonecrosis of the femoral head (ONFH) caused by steroids is a severe orthopedic disorder resulting from the use of high-dose steroid drugs, characterized by structural changes in the bone, joint dysfunction, and femoral head collapse. CircRNAs and miRNAs have increasingly been suggested to play pivotal roles in osteogenic differentiation and osteogenesis. Significant upregulation of circ_0058792 was observed in patients with steroid-induced ONFH. Bioinformatic analysis showed that circ_0058792 might act as a sponge for miR-181a-5p. This study further investigated the mechanisms underlying the role of circ_0058792 and miR-181a-5p in osteogenic differentiation in methylprednisolone-induced ONFH rats and MC3T3-E1 cells. The results showed a notable decrease in the serum of miR-181a-5p in methylprednisolone-induced ONFH rats. Silencing of circ_0058792 using siRNAs and overexpression of miR-181a-5p significantly increased alkaline phosphatase activity and matrix mineralization capacity. Additionally, markers for osteogenic differentiation were significantly upregulated in miR-181a-5p-transfected cells. However, overexpression of circ_0058792 and the addition of the miR-181a-5p inhibitor reversed this increase. Smad7 was identified to be miR-181a-5p's direct target and circ_0058792 was confirmed to be miR-181a-5p's competing endogenous RNA (ceRNA). Upregulation of miR-181a-5p promotes phosphorylation of Smad2 and Smad3. Furthermore, circ_0058792 and miR-181a-5p had opposing effects on Smad7 expression. Collectively, these findings indicate that circ_0058792 regulates osteogenic differentiation by sponging miR-181a-5p via the TGF-ß/Smad7 pathway. These findings elucidated the functions of circ_0058792 and miR-181a-5p in the regulation of steroid-induced ONFH. Our findings also indicated that circ_0058792 and miR-181a-5p are possible diagnostic markers and therapeutic targets for treating steroid-induced ONFH.
Asunto(s)
Necrosis de la Cabeza Femoral , MicroARNs , ARN Circular , Proteína smad7 , Animales , Diferenciación Celular/genética , Cabeza Femoral/metabolismo , Necrosis de la Cabeza Femoral/inducido químicamente , Necrosis de la Cabeza Femoral/genética , Necrosis de la Cabeza Femoral/metabolismo , Humanos , Metilprednisolona/toxicidad , Ratones , MicroARNs/genética , MicroARNs/metabolismo , Osteogénesis/genética , ARN Circular/genética , Ratas , Proteína smad7/genética , Proteína smad7/metabolismo , Esteroides/efectos adversosRESUMEN
BACKGROUND: Liver fibrosis and fibrosis-related hepatocarcinogenesis are a rising cause for morbidity and death worldwide. Although transforming growth factor-ß (TGF-ß) is a critical mediator of chronic liver fibrosis, targeting TGF-ß isoforms and receptors lead to unacceptable side effect. This study was designed to explore the antifibrotic effect of Compound kushen injection (CKI), an approved traditional Chinese medicine formula, via a therapeutic strategy of rebalancing TGF-ß/Smad7 signaling. METHODS: A meta-analysis was performed to evaluate CKI intervention on viral hepatitis-induced fibrosis or cirrhosis in clinical randomized controlled trials (RCTs). Mice were given carbon tetrachloride (CCl4 ) injection or methionine-choline deficient (MCD) diet to induce liver fibrosis, followed by CKI treatment. We examined the expression of TGF-ß/Smad signaling and typical fibrosis-related genes in hepatic stellate cells (HSCs) and fibrotic liver tissues by qRT-PCR, Western blotting, RNA-seq, immunofluorescence, and immunohistochemistry. RESULTS: Based on meta-analysis results, CKI improved the liver function and relieved liver fibrosis among patients. In our preclinical studies by using two mouse models, CKI treatment demonstrated promising antifibrotic effects and postponed hepatocarcinogenesis with improved liver function and histopathologic features. Mechanistically, we found that CKI inhibited HSCs activation by stabilizing the interaction of Smad7/TGF-ßR1 to rebalance Smad2/Smad3 signaling, and subsequently decreased the extracellular matrix formation. Importantly, Smad7 depletion abolished the antifibrotic effect of CKI in vivo and in vitro. Moreover, matrine, oxymatrine, sophocarpine, and oxysophocarpine were identified as material basis responsible for the antifibrosis effect of CKI. CONCLUSIONS: Our results unveil the approach of CKI in rebalancing TGF-ß/Smad7 signaling in HSCs to protect against hepatic fibrosis and hepatocarcinogenesis in both preclinical and clinical studies. Our study suggests that CKI can be a candidate for treatment of hepatic fibrosis and related oncogenesis.
Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Transducción de Señal/efectos de los fármacos , Proteína smad7/metabolismo , Factor de Crecimiento Transformador beta/metabolismo , Animales , Tetracloruro de Carbono/toxicidad , Carcinoma Hepatocelular/tratamiento farmacológico , Carcinoma Hepatocelular/patología , Línea Celular , Medicamentos Herbarios Chinos/uso terapéutico , Células Estrelladas Hepáticas/citología , Células Estrelladas Hepáticas/metabolismo , Humanos , Hígado/metabolismo , Hígado/patología , Cirrosis Hepática/inducido químicamente , Cirrosis Hepática/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/patología , Masculino , Medicina Tradicional China , Metaanálisis como Asunto , Ratones , Ratones Endogámicos C57BL , Interferencia de ARN , ARN Interferente Pequeño/metabolismo , Proteína smad7/antagonistas & inhibidores , Proteína smad7/genéticaRESUMEN
OBJECTIVE: Although the hypothalamus is crucial for peripheral metabolism control, the signals in specific neurons involved remain poorly understood. The aim of our current study was to explore the role of the hypothalamic gene mothers against decapentaplegic homolog 7 (Smad7) in peripheral glucose disorders. METHODS: We studied glucose metabolism in high-fat diet (HFD)-fed mice and middle-aged mice with Cre-mediated recombination causing 1) overexpression of Smad7 in hypothalamic proopiomelanocortin (POMC) neurons, 2) deletion of Smad7 in POMC neurons, and 3) overexpression of protein kinase B (AKT) in arcuate nucleus (ARC) in Smad7 overexpressed mice. Intracerebroventricular (ICV) cannulation of insulin was used to test the hypothalamic insulin sensitivity in the mice. Hypothalamic primary neurons were used to investigate the mechanism of Smad7 regulating hypothalamic insulin signaling. RESULTS: We found that Smad7 expression was increased in POMC neurons in the hypothalamic ARC of HFD-fed or middle-aged mice. Furthermore, overexpression of Smad7 in POMC neurons disrupted the glucose balance, and deletion of Smad7 in POMC neurons prevented diet- or age-induced glucose disorders, which was likely to be independent of changes in body weight or food intake. Moreover, the effect of Smad7 was reversed by overexpression of AKT in the ARC. Finally, Smad7 decreased AKT phosphorylation by activating protein phosphatase 1c in hypothalamic primary neurons. CONCLUSIONS: Our results demonstrated that an excess of central Smad7 in POMC neurons disrupts glucose balance by attenuating hypothalamic insulin signaling. In addition, we found that this regulation was mediated by the activity of protein phosphatase 1c.
Asunto(s)
Glucosa/metabolismo , Proopiomelanocortina/metabolismo , Proteína smad7/metabolismo , Animales , Núcleo Arqueado del Hipotálamo/metabolismo , Dieta Alta en Grasa , Metabolismo Energético , Expresión Génica/genética , Regulación de la Expresión Génica/genética , Hipotálamo/metabolismo , Insulina/metabolismo , Resistencia a la Insulina/fisiología , Leptina/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Neuronas/metabolismo , Obesidad/metabolismo , Proopiomelanocortina/genética , Proteínas Proto-Oncogénicas c-akt/metabolismo , Transducción de Señal , Proteína smad7/genéticaRESUMEN
BACKGROUND: Oxymatrine (OM), a quinolizidine alkaloid extracted from a herb Sophorae Flavescentis Radix, has been used to treat liver fibrotic diseases. However, the mechanism of its anti-fibrosis effects is still unclear. TGF-ß/Smad signaling and miR-195 have been proved to paly an important role in hepatic stellate cells (HSCs) activation and liver fibrosis. In this study, we investigated whether OM could inhibit HSCs activation through TGF-ß1/miR-195/Smads signaling or not. METHODS: First, the effects of OM on HSC-T6 in different concentrations and time points were tested by MTT assay. We choose three appropriate concentrations of OM as treatment concentrations in following experiment. By Quantitative Real-time PCR and Western Blot, then we investigated the effect of OM on miR-195, Smad7 and α-SMA's expressions to prove the correlation between OM and the TGF-ß1/miR-195/Smads signaling. Last, miR-195 mimic and INF-γ were used to investigate the relation between miR-195 and OM in HSC activation. RESULTS: Our results showed that the proliferation of HSC was significantly inhibited when OM concentration was higher than 200 µg/mL after 24 h, 100 µg/mL after 48 h and 10 µg/mL after 72 h. The IC50 of OM after 24, 48 and 72 h were 539, 454, 387 µg/mL respectively. OM could down-regulate miR-195 and α-SMA (P < 0.01), while up-regulate Smad7 (P < 0.05). In HSC-T6 cells transfected with miR-195 mimic and pretreated with OM, miR-195 and α-SMA were up-regulated (P < 0.05), and Smad7 was down-regulated (P < 0.05) . CONCLUSIONS: Given these results, OM could inhibit TGF-ß1 induced activation of HSC-T6 proliferation in a dose-dependent and time-dependent manner to some extent. We proved that OM inhibited HSC activation through down-regulating the expression of miR-195 and up-regulating Smad7.
Asunto(s)
Alcaloides/farmacología , Células Estrelladas Hepáticas/efectos de los fármacos , MicroARNs/metabolismo , Extractos Vegetales/farmacología , Quinolizinas/farmacología , Proteína smad7/metabolismo , Sophora/química , Factor de Crecimiento Transformador beta1/metabolismo , Animales , Línea Celular , Proliferación Celular/efectos de los fármacos , Células Estrelladas Hepáticas/metabolismo , Humanos , Interferón gamma/genética , Interferón gamma/metabolismo , MicroARNs/genética , Ratas , Transducción de Señal/efectos de los fármacos , Proteína smad7/genética , Factor de Crecimiento Transformador beta1/genéticaRESUMEN
BACKGROUND/AIMS: Salvia miltiorrhiza (SM) contains four major aqueous active ingredients, which have been isolated, purified and identified as danshensu (DSS), salvianolic acid A (Sal-A), salvianolic acid B (Sal-B) and protocatechuic aldehyde (PAL), totally abbreviated as SABP. Although SM is often used to treat various cardiovascular diseases in traditional Chinese medicine, the efficacy and function of optimal compatibility ratio of SM's active ingredients (SABP) in the prevention and treatment of cardiovascular diseases remain uncertain. This study investigated antihypertensive effect and underlying mechanisms of SABP vs. SM lyophilized powder (SMLP) in spontaneously hypertensive rats (SHR) and to establish the ratio of the optimal compatibility of DSS, Sal-A, Sal-B and PAL in improving cardiovascular functions. METHODS: The SHRs were treated with either SABP or SMLP and their systolic blood pressures (SBP) were monitored. The isolated thoracic aorta of SHRs was segregated for immunohistochemistry, Hematoxylin-Eosin stain and mRNA and protein expression of NOX4, TGF-ß1, Col-I, ET-1, α-SMA and Smad7. Moreover, the adventitial fibroblasts (AFs) were isolated and cultured from SD rats' aorta and the reactive oxygen species (ROS) production was determined after SABP or SMLP treatment. RESULTS: SABP, but not SMLP, significantly reduced SBP, which were accompanied by the inhibited morphological changes in the thoracic aorta and the reduced mRNA and protein expression of NOX4, TGF-ß1, Col-I, ET-1 and α-SMA, but the increased Smad 7 expression in SHRs. Moreover, SABP also resulted in a decreased ROS production in AFs of SD rats. CONCLUSIONS: These results indicate that SABP, but not SMLP, treatment potently inhibits hypertension through improvements of vascular remodeling and oxidative stress. The present study provides new evidence that the efficacy and function from optimal compatibility ratio of SM active ingredients is much better than its lyophilized powder, which represents a strategy to develop SM's new beneficial effect in improving cardiovascular functions.
Asunto(s)
Presión Sanguínea/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales/farmacología , Salvia miltiorrhiza/química , Remodelación Vascular/efectos de los fármacos , Agua/química , Actinas/genética , Actinas/metabolismo , Angiotensina II/sangre , Animales , Aorta Torácica/efectos de los fármacos , Aorta Torácica/patología , Proliferación Celular/efectos de los fármacos , Colágeno Tipo I/metabolismo , Endotelina-1/sangre , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Fibroblastos/patología , Masculino , Malondialdehído/sangre , NADPH Oxidasa 4 , NADPH Oxidasas/metabolismo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas Endogámicas SHR , Ratas Sprague-Dawley , Especies Reactivas de Oxígeno/metabolismo , Proteína smad7/genética , Proteína smad7/metabolismo , Superóxido Dismutasa/sangre , Sístole/efectos de los fármacos , Factor de Crecimiento Transformador beta1/sangre , Factor de Crecimiento Transformador beta1/genéticaRESUMEN
In this research, compound Maqin decoction (CMD) has been shown to positively affect in airway inflammation of asthma models. We evaluated the effects of CMD on the expression of transforming growth factor (TGF)-ß1/Smad proteins, interleukin (IL)-17, and IL-10 in lung tissue of asthmatic rats. Asthma was induced in a rat model using ovalbumin. After a 4-week treatment with CMD, rats were killed to evaluate the expression of TGF-ß1 and Smad proteins in lung tissue. IL-10 and IL-17 levels in lung tissue homogenates were determined by ELISA. The expression of TGF-ß1 and Smad3 protein increased, whereas expression of Smad7 protein decreased upon high-dose or low-dose treatment with CMD or by intervention with dexamethasone, compared to the control. There was a significant difference between treatment with a high dose CMD and the control treatment, but no significant difference was found between high-dose CMD treatment and dexamethasone intervention. The expression of TGF-ß1 and Smad7 protein increased, whereas the expression of Smad3 protein decreased in the model group compared to other groups. In the CMD high-dose group, low-dose group, and dexamethasone intervention group, the IL-17 concentrations in lung tissue homogenates were decreased, while IL-10 levels were increased. Again, there was a significant difference between CMD high-dose and control treatment, but not between CMD high-dose treatment and dexamethasone intervention. Thus, positive effects of CMD against asthmatic airway remodeling may be due to its regulatory effect on TGF-ß1, Smad3, and Smad7 protein levels and on cytokines such as IL-10 and IL-17.
Asunto(s)
Antiasmáticos/farmacología , Asma/tratamiento farmacológico , Pulmón/efectos de los fármacos , Extractos Vegetales/farmacología , Factor de Crecimiento Transformador beta1/inmunología , Remodelación de las Vías Aéreas (Respiratorias)/efectos de los fármacos , Animales , Antiasmáticos/aislamiento & purificación , Asma/inducido químicamente , Asma/inmunología , Asma/patología , Berberidaceae/química , Dexametasona/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Elaeagnaceae/química , Ephedra/química , Regulación de la Expresión Génica , Interleucina-10/genética , Interleucina-10/inmunología , Interleucina-17/genética , Interleucina-17/inmunología , Pulmón/inmunología , Pulmón/patología , Masculino , Ovalbúmina , Extractos Vegetales/química , Ratas , Ratas Sprague-Dawley , Scutellaria baicalensis/química , Transducción de Señal , Proteína smad3/genética , Proteína smad3/inmunología , Proteína smad7/genética , Proteína smad7/inmunología , Factor de Crecimiento Transformador beta1/genética , Xanthium/químicaRESUMEN
Dermal wound healing, in which transforming growth factor beta 1 (TGFß1) plays an important role, is a complex process. Previous studies suggest that vitamin D has a potential regulatory role in TGFß1 induced activation in bone formation, and there is cross-talk between their signaling pathways, but research on their effects in other types of wound healing is limited. The authors therefore wanted to explore the role of vitamin D and its interaction with low concentration of TGFß1 in dermal fibroblast-mediated wound healing through an in vitro study. Human dermal fibroblasts were treated with vitamin D, TGFß1, both, or vehicle, and then the wound healing functions of dermal fibroblasts were measured. To further explore possible mechanisms explaining the synergistic effect of vitamin D and TGFß1, targeted gene silencing of the vitamin D receptor was performed. Compared to either factor alone, treatment of fibroblasts with both vitamin D and low concentration of TGFß1 increased gene expression of TGFß1, connective tissue growth factor, and fibronectin 1, and enhanced fibroblast migration, myofibroblast formation, and collagen production. Vitamin D receptor gene silencing blocked this synergistic effect of vitamin D and TGFß1 on both collagen production and myofibroblast differentiation. Thus a synergistic effect of vitamin D and low TGFß1 concentration was found in dermal fibroblast-mediated wound healing in vitro. This study suggests that supplementation of vitamin D may be an important step to improve wound healing and regeneration in patients with a vitamin D deficiency.
Asunto(s)
Calcitriol/farmacología , Dermis/efectos de los fármacos , Fibroblastos/efectos de los fármacos , Factor de Crecimiento Transformador beta1/farmacología , Vitaminas/farmacología , Cicatrización de Heridas/efectos de los fármacos , Adulto , Diferenciación Celular/efectos de los fármacos , Movimiento Celular/efectos de los fármacos , Células Cultivadas , Cromatografía Liquida , Factor de Crecimiento del Tejido Conjuntivo/efectos de los fármacos , Factor de Crecimiento del Tejido Conjuntivo/genética , Dermis/metabolismo , Sinergismo Farmacológico , Femenino , Fibroblastos/metabolismo , Fibronectinas/efectos de los fármacos , Fibronectinas/genética , Humanos , Hidroxiprolina/metabolismo , Técnicas In Vitro , Espectrometría de Masas , Miofibroblastos/efectos de los fármacos , Reacción en Cadena en Tiempo Real de la Polimerasa , Receptores de Calcitriol/efectos de los fármacos , Receptores de Calcitriol/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Proteína Smad2/efectos de los fármacos , Proteína Smad2/genética , Proteína smad3/efectos de los fármacos , Proteína smad3/genética , Proteína smad7/efectos de los fármacos , Proteína smad7/genética , Factor de Crecimiento Transformador beta1/efectos de los fármacos , Factor de Crecimiento Transformador beta1/genéticaRESUMEN
BACKGROUND: The aim of this study was to explore the effect of Tongxinluo on myocardial fibrosis in diabetic rats and its possible mechanism of action. METHODS: Diabetic rat models were established and then divided into three groups: control, diabetes, and Tongxinluo groups. Heart function and myocardial interstitial collagen volume fraction were investigated, and the protein and mRNA expression levels of transforming growth factor beta 1 (TGF-ß1), Smad3, and Smad7 were measured. RESULTS: Heart function was clearly abnormal in the diabetes group compared with that in the control group, and the collagen volume fraction and mRNA expression levels of TGF-ß1 and Smad3 were higher. However, the protein and mRNA expression levels of Smad7 were lower. In the Tongxinluo group, it was observed that these indicators were improved. CONCLUSION: Tongxinluo was effective for the prevention and treatment of myocardial fibrosis in diabetic rats. It probably mediates the expressions of TGF-ß1, Smad3, and Smad7 in rat cardiomyocytes to reduce the occurrence of myocardial fibrosis in diabetic rats.
Asunto(s)
Diabetes Mellitus Experimental/tratamiento farmacológico , Medicamentos Herbarios Chinos/uso terapéutico , Miocardio/patología , Animales , Diabetes Mellitus Experimental/complicaciones , Diabetes Mellitus Experimental/fisiopatología , Fibrosis , Masculino , Miocardio/metabolismo , Ratas , Ratas Sprague-Dawley , Proteína smad3/genética , Proteína smad7/genética , Estreptozocina , Factor de Crecimiento Transformador beta1/genéticaRESUMEN
OBJECTIVE: To discuss whether asiaticosides could effectively reduce the endothelial cell damage as a biochemical modulator, so as to further inhibit the post-stenting intima-media membrane hyperplasia. METHOD: Human aortic smooth muscle cells and aortic fibroblasts were selected and divided into the blank group, the rapamycin group and the asiaticoside group and the rapamycin and asiaticoside group. The expressions of muscle cells and fibroblasts TGF-beta1, Smad7 and I-collagen gene were determined by RT-PCR. The expression quantity of I-collagen protein was assayed by ELISA. The coefficient of drug interaction (CDI) between rapamycin and asiaticoside was calculated. Additionally, 16 Chinese mini-swines were randomly divided into group A and group B. One sirolimus drug-eluting stent of the same type was implanted after the high-pressure pre-expansion of anterior descending artery balloon. After the operation, the group A was intravenously injected with normal saline 30 mL x d(-1). Whereas the group B was intravenously injected with asiaticoside 30 mg x kg(-1) x d(-1)(diluted to 30 mL). The expressions of plasma vWF of the two groups were measured at the 7th and 14th days after the operation. At the 28th day after the operation, tissues of the stented vessel segments were sliced and stained to calculate the vessel area, inner stent area, lumen area and neointima area RESULT: Compared with the control group, the combination group showed significant up-regulation in smooth muscle cells and fibroblast Smad7 gene, down-regulation in TGF-beta, and obvious inhibition of I-collagen gene expression (P < 0.01). As for smooth muscle cells, there was no difference in the expression of I-collagen between the combination group and the rapamycin group, with CDI at 0. 83. As for fibroblasts, there was a significant difference in the expression of I-collagen between the combination group and the rapamycin group (P < 0.05), with CDI at 0.77. Plasma vWF of the group B was significantly lower than that of the group A (P < 0.05) at the 7th and 14th days after the operation. At the 28th day after the operation, no difference was observed in vessel area and stent area between the two groups. However, the lumen area in the group B was significantly larger than that of the group A(P < 0.05), and the neointima area of the group B was significantly smaller than that of the group A (P < 0.05). CONCLUSION: As an effective biochemical modulator for rapamycin, asiaticosides could inhibit TGF-beta expression, significantly decrease the synthesis and secretion of extracellular matrix, further inhibit the post-stenting intima-media membrane hyperplasia and reduce the endothelial cell damage by effectively up-regulate the expression of Smad7 protein.
Asunto(s)
Reestenosis Coronaria/prevención & control , Medicamentos Herbarios Chinos/administración & dosificación , Triterpenos/administración & dosificación , Animales , Colágeno/genética , Colágeno/metabolismo , Reestenosis Coronaria/tratamiento farmacológico , Reestenosis Coronaria/cirugía , Humanos , Hiperplasia/tratamiento farmacológico , Hiperplasia/genética , Hiperplasia/metabolismo , Hiperplasia/prevención & control , Proteína smad7/genética , Proteína smad7/metabolismo , Stents/efectos adversos , Porcinos , Factor de Crecimiento Transformador beta1/genética , Factor de Crecimiento Transformador beta1/metabolismoRESUMEN
BACKGROUND: In traditional Chinese medicine, astragalus injection is used to treat diabetic nephropathy (DN). The current study was conducted to determine the effects of astragalus injection on DN by assessing potential modulation of the transforming growth factor beta TGFß/Smad signaling pathway. METHODS: Diabetic, male KKAy mice, aged 14 weeks were randomly divided into a model group and an astragalus treatment group, while age-matched male C57BL/6J mice were selected as controls. The treatment group received daily intraperitoneal injections of astragalus (0.03 ml/10 g.d), while the model group received injections of an equivalent volume of saline. Mice were euthanized after 24 weeks. Serum samples were obtained from animals in each group, and blood glucose, creatinine, and urea nitrogen levels were measured. Tissue samples from the kidney were used for morphometric studies. The expression of TGFß1, TGFßR-Ι, Smad3, and Smad7 were evaluated using reverse transcription-polymerase chain reaction (RT-PCR), and western blot analysis. RESULTS: Mice in the model group became obese, and suffered complications, including hyperglycemia, polyuria, and proteinuria. Astragalus treatment significantly reduced albuminuria, improved renal function, and ameliorated changes in renal histopathology. Moreover, administration of astragalus injection increased Smad7 expression, and inhibited the expression of TGFßR-Ι, Smad3 and its phosphorylation, and decreased the mRNA level of TGFß1. CONCLUSIONS: The TGFß/Smad signaling pathway plays an important role in the development of DN. Administration of astragalus injection could prevent or mitigate DN by rebalancing TGFß/Smad signaling, and could play a protective role in DN-induced renal damage in KKAy mice.
Asunto(s)
Planta del Astrágalo/química , Diabetes Mellitus Experimental/complicaciones , Nefropatías Diabéticas/tratamiento farmacológico , Medicamentos Herbarios Chinos/administración & dosificación , Riñón/efectos de los fármacos , Proteína smad3/metabolismo , Factor de Crecimiento Transformador beta/metabolismo , Animales , Glucemia/metabolismo , Diabetes Mellitus Experimental/genética , Diabetes Mellitus Experimental/metabolismo , Nefropatías Diabéticas/genética , Nefropatías Diabéticas/metabolismo , Humanos , Riñón/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Transducción de Señal/efectos de los fármacos , Proteína smad3/genética , Proteína smad7/genética , Proteína smad7/metabolismoRESUMEN
This study is to investigate the effect of artesunate on transforming growth factor-beta1 (TGF-beta1) induced epithelial-mesenchymal transition (EMT) and its possible mechanism. After the in vitro cultured RLE-6TN cells were treated with TGF-beta1 then artesunate intervened on it, after 24 h, expression of the markers of mesenchymal cell was assayed using Western blotting and real-time PCR analysis. Western blotting was also used to detect the effect of TGF-beta1 on the Smad3 and Smad7 expressions of RLE-6TN cells. Morphological alterations were examined by phase-contrast microscope, and ultrastructure changes by electron microscope. Incubation of RLE-6TN cells with TGF-beta1 resulted in the up-regulation of the expression of the mesenchymal cell markers, after artesunate intervened on it, resulted in the down-regulation of the expression. Meanwhile, incubation with artesunate intervened on RLE-6TN cells could lead to the apparent down-regulation of the expression of Smad3 and up-regulation of Samd7 and the transition of RLE-6TN cells to mesenchymal-like by TGF-beta1 induction, after artesunate intervened on it, RLE-6TN cells to epithelial-like. TGF-beta1 induced epithelial-mesenchymal transition process; artesunate can inhibit TGF-beta1-induced epithelial-mesenchymal transition process, the possible mechanism is up-regulation of the expression of Smad7 and down-regulation of the expression of Smad3, meanwhile inhibits phosphorylation of Smad3.
Asunto(s)
Artemisininas/farmacología , Células Epiteliales/citología , Transición Epitelial-Mesenquimal/efectos de los fármacos , Alveolos Pulmonares/citología , Factor de Crecimiento Transformador beta1/farmacología , Actinas/genética , Actinas/metabolismo , Animales , Artemisia/química , Artemisininas/aislamiento & purificación , Artesunato , Línea Celular , Proliferación Celular/efectos de los fármacos , Células Epiteliales/metabolismo , Fibrosis Pulmonar Idiopática/patología , Plantas Medicinales/química , ARN Mensajero/metabolismo , Ratas , Proteína smad3/genética , Proteína smad3/metabolismo , Proteína smad7/genética , Proteína smad7/metabolismo , Vimentina/genética , Vimentina/metabolismoRESUMEN
OBJECTIVE: Increasing evidence shows that TGF-ß1 is a key mediator in diabetic nephropathy (DN) and induces renal fibrosis positively by Smad3 but negatively by Smad7. However, treatment of DN by blocking the TGF-ß/Smad pathway remains limited. The present study investigated the anti-fibrotic effect of a traditional Chinese medicine, Chaihuang-Yishen granule (CHYS), on DN. RESEARCH DESIGN AND METHODS: Protective role of CHYS in DN was examined in an accelerated type 1 DN induced by streptozotocin in uninephrectomized Wistar rats. CHYS, at a dose of 0.56 g/kg body weight, was administered by a daily gastric gavage for 20 weeks and the therapeutic effect and potential mechanisms of CHYS on diabetic kidney injury were examined. RESULTS: Treatment with CHYS attenuated diabetic kidney injury by significantly inhibiting 24-h proteinuria and progressive renal fibrosis including glomerulosclerotic index, tubulointerstitial fibrosis index, and upregulation of extracellular matrix (collagen I, IV, and fibronectin), despite the same levels of blood glucose. Further studies revealed that inhibition of renal fibrosis in CHYS-treated diabetic rats was associated with inhibition of TGF-ß1/Smad3 signaling as demonstrated by upregulation of Smad7 but downregulation of TGF-ß1, TGF-ß receptors, activation of Smad3, and expression of miRNA-21. CONCLUSIONS: CHYS may be a therapeutic agent for DN. CHYS attenuates DN by blocking TGF-ß/Smad3-mediated renal fibrosis.
Asunto(s)
Nefropatías Diabéticas/tratamiento farmacológico , Medicamentos Herbarios Chinos/farmacología , Hipoglucemiantes/farmacología , Receptores de Factores de Crecimiento Transformadores beta/antagonistas & inhibidores , Transducción de Señal/efectos de los fármacos , Proteína smad3/antagonistas & inhibidores , Factor de Crecimiento Transformador beta1/antagonistas & inhibidores , Animales , Glucemia/metabolismo , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/genética , Diabetes Mellitus Experimental/patología , Nefropatías Diabéticas/genética , Nefropatías Diabéticas/metabolismo , Nefropatías Diabéticas/patología , Regulación de la Expresión Génica , Masculino , Ratas , Ratas Wistar , Receptores de Factores de Crecimiento Transformadores beta/genética , Receptores de Factores de Crecimiento Transformadores beta/metabolismo , Proteína smad3/genética , Proteína smad3/metabolismo , Proteína smad7/agonistas , Proteína smad7/genética , Proteína smad7/metabolismo , Factor de Crecimiento Transformador beta1/genética , Factor de Crecimiento Transformador beta1/metabolismoRESUMEN
The role of transforming growth factor-ß1 (TGFß1) and Smad signalling has not been established in psoriasis treatment. We aimed to investigate the effect of combined treatment with salt water soaks and ultraviolet radiation on the expression of TGFß1/Smad signalling proteins in a psoriatic model. We studied mRNA expression (real-time RT-PCR) of TGFß1, TGFß receptor type I (TGFßRI), Smad2, Smad3, Smad4, Smad7, minichromosome maintenance protein 7, and involucrin in normal as well as psoriatic epidermis models (PEM) which were treated for three consecutive days with differently concentrated salt water solutions [(3% NaCl; 30% NaCl, 30% Dead Sea salt water (DSSW)] and subsequent narrowband ultraviolet B (NB-UVB). In PEM, TGFß1 and Smad3 was significantly increased as compared to normal epidermis models. By contrast, TGFßRI mRNA was significantly decreased in PEM. Significant increase of mRNA levels of TGFß1, TGFßRI, Smad2 and Smad3 was predominantly observed in non-irradiated and irradiated PEM pre-treated with 30% NaCl and/or DSSW which was paralleled by increase of involucrin mRNA. In PEM pre-treated with DSSW, TGFßRI, Smad2, Smad3, Smad4, and Smad7 mRNA was significantly higher in irradiated PEM when compared to non-irradiated samples. It has been shown that TGFß1/Smad signalling is altered in a psoriatic model and may play a role in the mode of action of salt water soaks and NB-UVB phototherapy of psoriasis.
Asunto(s)
Psoriasis/terapia , Proteínas Smad/metabolismo , Cloruro de Sodio/uso terapéutico , Factor de Crecimiento Transformador beta1/metabolismo , Terapia Ultravioleta , Línea Celular , Epidermis/metabolismo , Humanos , Queratinocitos/metabolismo , Componente 7 del Complejo de Mantenimiento de Minicromosoma/biosíntesis , Componente 7 del Complejo de Mantenimiento de Minicromosoma/genética , Componente 7 del Complejo de Mantenimiento de Minicromosoma/metabolismo , Precursores de Proteínas/biosíntesis , Precursores de Proteínas/genética , Precursores de Proteínas/metabolismo , Psoriasis/metabolismo , ARN Mensajero/biosíntesis , Receptores de Factores de Crecimiento Transformadores beta/biosíntesis , Receptores de Factores de Crecimiento Transformadores beta/genética , Receptores de Factores de Crecimiento Transformadores beta/metabolismo , Transducción de Señal , Proteína Smad2/biosíntesis , Proteína Smad2/genética , Proteína Smad2/metabolismo , Proteína smad3/biosíntesis , Proteína smad3/genética , Proteína smad3/metabolismo , Proteína Smad4/biosíntesis , Proteína Smad4/genética , Proteína Smad4/metabolismo , Proteína smad7/biosíntesis , Proteína smad7/genética , Proteína smad7/metabolismo , Factor de Crecimiento Transformador beta1/biosíntesis , Factor de Crecimiento Transformador beta1/genéticaRESUMEN
OBJECTIVE: To evaluate the effect of Notoginseng Radix on hepatic expression of transforming growth factor beta1 (TGF-beta1) and connective tissue growth factor (CTGF) in rats with alcoholic liver disease (ALD), in order to discuss its protective effect on alcoholic cirrhosis. METHOD: Fifty SD male rats were divided into the normal control group, the model group, the high-dose and low-dose Notoginseng Radix groups (3.0, 12.0 g x kg(-1)) and the magnesium isoglycyrrhizinate group (24 mg x kg(-1)), with 10 rats in each group. Apart from the control group, other groups were administered with ethanol-cornoil-pyrazole for 14 weeks to establish the alcoholic liver disease model. During the establishment of the model, the high-dose and low-dose Notoginseng Radix groups were administered with 12 g x kg(-1) x d(-1) Notoginseng Radix for 14 weeks, once everyday. Efforts were made to detect liver function, pathology with Masson staining, and the expressions of TGF-beta1, Smad3, Smad7 and CTGF mRNA. RESULT: Compared with the rats in model group, rats in Notoginseng Radix groups showed significant reduction in liver ALT, AST, collagen fiber deposition, and TGF-beta1, Smad3 and CTGF mRNA expressions in liver tissues, with the increase in the expression quantity of Smad7 mRNA. There were differences between the Notoginseng Radix groups. No significant difference was observed between the high-dose Notoginseng Radix group and the magnesium isoglycyrrhizinate group. CONCLUSION: Notoginseng Radix can affect TGF-beta1/Smads signaling pathway and reduce the expression of CTGF.
Asunto(s)
Factor de Crecimiento del Tejido Conjuntivo/genética , Medicamentos Herbarios Chinos/administración & dosificación , Hepatopatías Alcohólicas/tratamiento farmacológico , Hepatopatías Alcohólicas/genética , Panax notoginseng/química , Proteína smad3/genética , Proteína smad7/genética , Factor de Crecimiento Transformador beta1/genética , Animales , Factor de Crecimiento del Tejido Conjuntivo/metabolismo , Expresión Génica/efectos de los fármacos , Humanos , Hepatopatías Alcohólicas/metabolismo , Masculino , Ratas , Ratas Sprague-Dawley , Proteína smad3/metabolismo , Proteína smad7/metabolismo , Factor de Crecimiento Transformador beta1/metabolismoRESUMEN
Panax notoginseng is a common Chinese herb extensively used in Chinese medical practice for the treatment of cardiovascular diseases. The present study aimed to evaluate the effects of Panax notoginseng flower extract (PNFE) on the TGF-ß/Smad signal transduction pathway in heart remodeling of human chymase transgenic mice. After treatment with PNFE and soybean trypsin inhibitor (SBTI), the left ventricular mass indexes (LVMIs) of transgenic and normal C57 BL/6 mice were analyzed. The mRNA expression of chymase, TGF-ß1, Smad2, Smad3 and Smad7 in myocardium was assessed with RT-PCR, while the protein expression in myocardium was detected by western blotting. The results showed that PNFE and SBTI treatment led to a significant reduction in LVMIs in transgenic mice, indicating a beneficial effect on left ventricular remodeling. Mechanistically, PNFE and SBTI treatment attenuated the mRNA expression of chymase, TGF-ß1, Smad2 and Smad3, as well as the protein expression in the myocardium tissues of the transgenic mouse model. By contrast, PNFE and SBTI treatment markedly up-regulated the mRNA and protein expression of Smad7. It was concluded that PNFE was able to improve the ventricular hypertrophy state in human chymase transgenic mice through regulation of the expression of mRNA and protein of TGF-ß/Smad in ventricular tissues.
Asunto(s)
Quimasas/metabolismo , Medicamentos Herbarios Chinos/farmacología , Transducción de Señal/efectos de los fármacos , Proteína Smad2/metabolismo , Factor de Crecimiento Transformador beta/metabolismo , Remodelación Ventricular/efectos de los fármacos , Animales , Quimasas/genética , Humanos , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Miocardio/metabolismo , ARN Mensajero/metabolismo , Proteína Smad2/genética , Proteína smad3/genética , Proteína smad3/metabolismo , Proteína smad7/genética , Proteína smad7/metabolismo , Factor de Crecimiento Transformador beta/genética , Inhibidores de Tripsina/farmacología , Regulación hacia ArribaRESUMEN
Bone homeostasis can be compromised by an increase in osteoclast-mediated resorption and/or a decrease in osteoblast-mediated bone deposition. While many efforts have focused on treating osteoclast resorption, there has been less emphasis on identifying strategies for promoting osteoblast function. Herein, we describe a high-throughput screening assay to select for small molecules that augment bone morphogenetic protein-2 (BMP-2)-mediated osteoblast lineage commitment. After an initial screen of 5405 compounds; consisting of FDA-approved drugs, known bioactives, and compounds with novel chemical makeup, we identified 45 small molecules that promoted osteoblast commitment. Of the 45 candidates, there was a broad array of classes that included nine retinoid analogs/derivatives and four immunosuppressants, notably rapamycin and FK-506, which were chosen for further study. Treatment of osteoblast precursor cells with rapamycin or FK-506, either alone, or synergistically with BMP-2, increased levels of phospho-Smad 1/5/8 protein and transcription of Runx-2, Osx and Smad-7, consistent with a role in promoting osteoblast differentiation. Only FK-506 was able to enhance osteocalcin transcripts and Alizarin Red staining, both late markers for differentiation. When osteoblast differentiation was suppressed with exogenous TGF-ß1 treatment, rapamycin (but not FK-506) was able to rescue expression of differentiation markers, indicating distinct but overlapping activity of these compounds. Collectively, these data add to an understanding of pathways engaged in osteoblastogenesis, support a role for non-redundant immunosuppressant signaling, and provide a novel approach for the discovery of potentially therapeutic compounds that affect bone remodeling.
Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Ensayos Analíticos de Alto Rendimiento/métodos , Inmunosupresores/farmacología , Osteoblastos/citología , Osteoblastos/efectos de los fármacos , Bibliotecas de Moléculas Pequeñas/farmacología , Células 3T3 , Animales , Proteína Morfogenética Ósea 2/administración & dosificación , Proteína Morfogenética Ósea 2/farmacología , Remodelación Ósea/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/genética , Diferenciación Celular/fisiología , Línea Celular , Subunidad alfa 1 del Factor de Unión al Sitio Principal/genética , Sinergismo Farmacológico , Inmunosupresores/administración & dosificación , Ratones , Osteoblastos/metabolismo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Transducción de Señal/efectos de los fármacos , Sirolimus/administración & dosificación , Sirolimus/farmacología , Proteína smad7/genética , Bibliotecas de Moléculas Pequeñas/administración & dosificación , Factor de Transcripción Sp7 , Tacrolimus/administración & dosificación , Tacrolimus/farmacología , Factores de Transcripción/genética , Factor de Crecimiento Transformador beta1/administración & dosificaciónRESUMEN
AIM OF THE STUDY: Puerarin is a pure extract from traditional Chinese medicine Kudzu root. It has been used to treat hypertension and angina pectoris. In our previous study, it showed a protective effect against cardiac hypertrophy in rats. This study was to observe effects of puerarin on expression of cardiac transforming growth factor ß(1) (TGF-ß(1)), Smad3 and Smad7 mRNA in the spontaneously hypertensive rat (SHR), and to explore its possible mechanism of myocardial protection. MATERIALS AND METHODS: Thirty-five 12-week-old SHRs were randomly allocated into 5 groups of 7 rats as follows: 3 groups which received intraperitoneal (i.p.) puerarin (100 mg kg(-1), 50 mg kg(-1) and 25 mg kg(-1)), 1 group which received captopril (30 mg kg(-1), i.g.) and 1 control group of untreated SHRs. In addition, a control group of 7 Wistar-Kyoto (WKY) rats was established. Both control groups received i.p. injections of saline. All rats were treated for six weeks. At the end of this period all rats were sacrificed, and their hearts were quickly removed for semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis. RESULTS: Compared with WKY control group, expression of TGF-ß(1) and Smad3 mRNA was increased (p<0.01) and Smad7 mRNA expression was decreased in SHR control group (p<0.01). High- and middle-dose puerarin decreased the expression of TGF-ß(1) and Smad3 mRNA (p<0.01) and increased the expression of Smad7 mRNA (p<0.05). CONCLUSION: Puerarin reduces expression of TGF-ß(1) and Smad3 mRNA and increases that of Smad7 mRNA in SHR myocardium. These changes in gene expression may be a mechanism by which puerarin provides myocardial protection from hypertension.
Asunto(s)
Hipertensión/metabolismo , Isoflavonas/farmacología , Miocardio/metabolismo , Proteína smad3/genética , Proteína smad7/genética , Factor de Crecimiento Transformador beta1/genética , Animales , Medicamentos Herbarios Chinos/farmacología , Expresión Génica/efectos de los fármacos , Masculino , ARN Mensajero/metabolismo , Ratas , Ratas Endogámicas SHR , Ratas Endogámicas WKYRESUMEN
BACKGROUND: Transforming growth factor ß1 (TGF-ß1), connective tissue growth factor (CTGF) and Smad7 are potent components of fibrogenesis-related signal transduction pathways. Renal fibrosis is the major pathological change in the rat models with unilateral ureteral obstruction (UUO). Investigating the effects of gypenosides (GPs) on the expression of fibrogenesis-related genes in the UUO model may lead to the development of effective therapy for renal diseases. METHODS: Rats were randomly divided into 3 experimental groups: (i) sham operation rats treated with saline (sham group), (ii) UUO model rats treated with saline (control group) and (iii) UUO model rats treated with GPs (GPs group). Blood urea nitrogen and serum creatinine were detected as the measurement of renal function. UUO-treated kidney tissues were taken for assessment of renal damage index and determination of related gene expression through immunohistochemistry and RT-PCR. RESULTS: UUO-induced tubulointerstitial damage and fibrosis were attenuated by the application of GPs (day 3 and day 7, p<0.01; day 14, p<0.05). The expression of TGF-ß1 and CTGF was significantly reduced with GPs treatment (TGF-ß1, p<0.01; CTGF, p<0.05). Smad7 expression was elevated with GPs treatment at days 7 and 14 (p<0.01). GPs' protective effects on renal function were also demonstrated with this UUO model. CONCLUSIONS: These results suggest that UUO-induced tubulointerstitial fibrosis can be effectively attenuated by GPs application. GPs-mediated down-regulation of TGF-ß1 and CTGF and up-regulation of Smad7 are essential for their effects of antifibrogenesis.
Asunto(s)
Enfermedades Renales/prevención & control , Riñón/efectos de los fármacos , Obstrucción Ureteral/tratamiento farmacológico , Actinas/metabolismo , Animales , Biomarcadores/sangre , Nitrógeno de la Urea Sanguínea , Factor de Crecimiento del Tejido Conjuntivo/genética , Factor de Crecimiento del Tejido Conjuntivo/metabolismo , Creatinina/sangre , Modelos Animales de Enfermedad , Femenino , Fibrosis , Regulación de la Expresión Génica , Gynostemma , Inmunohistoquímica , Riñón/metabolismo , Riñón/patología , Enfermedades Renales/genética , Enfermedades Renales/metabolismo , Enfermedades Renales/patología , Masculino , Extractos Vegetales/farmacología , ARN Mensajero/metabolismo , Ratas , Ratas Wistar , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Proteína smad7/genética , Proteína smad7/metabolismo , Factores de Tiempo , Factor de Crecimiento Transformador beta1/genética , Factor de Crecimiento Transformador beta1/metabolismo , Obstrucción Ureteral/genética , Obstrucción Ureteral/metabolismoRESUMEN
OBJECTIVE: To explore the mechanism of action of Longbixiao Capsule (LBXC, a Chinese herbal preparation) on human prostatic stromal cell cultured in vitro. METHODS: Nine Japan rabbits were assigned to 3 groups. The high, low dose group was given LBXC [2.0 g/(kg x d), 1.0 g/(kg x d)] by gastro gavage respectively, while equal volume of normal saline was given by gastrog avage 60 rats in the control group, all twice a day with an infeval of 12 h, for 3 successive days. The serum collected at 3 h after the last gastro gavage was added into cell culture fluid. Rabbit's serum containing LBXC was incubated with the cultured stromal cells, and the levels of cell proliferation and apoptosis were determined using relative techniques as TUNEL, ELISA, and immunocytochemistry. Besides, Real-time RT-PCR was applied to detect the mRNA expressions of TGF-beta1, and Smad7 in the stromal cells. RESULTS: The cell proliferation showed culture time dependence in all groups. The proliferation in the drug-serum treated groups was lower than that in the control group, and it was lower in the high dose treated group than in the low dose treated group (all P < 0.01). The unfavorable growth did not occur morphologically after being cultured for 48 h and showed insignificant difference between various groups. Cell apoptosis was not found excepting for a few appeared in the high dose treated group (with a little amount of apoptotic cells occurring). After treatment, the expressions of TGF-beta, and Smad7 were lower in the low dose treated group and high dose treated group than in the control group (P < 0.01). There was not statistical difference between the low dose treated group and high dose treated group (P > 0.05). CONCLUSION: LBXC could reduce the expressions of TGF-beta1, and smad7 mRNA in stromal cells and inhibit the stromal cell proliferation, but its effect on promoting cell apoptosis is unobvious.